SCHOTT Pharma with positive start to financial year 2026; outlook confirmed

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma with positive start to financial year 2026; outlook confirmed 11.02.2026 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. SCHOTT Pharma with positive start to financial year 2026; outlook confirmed

• Revenue increase in Q1 2026 by 4.8% at constant currencies to EUR 240.2 million (reported: 3.8%)
• EBITDA margin was 27.1% (Q1 2025: 25.4%)
• Share of high‑value solutions (HVS) remains high at 57%, on par with the strong result of the 2025 financial year (Q1 2025: 55%)
• Outlook for the 2026 financial year confirmed

SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has made a positive start to the 2026 financial year. Revenue in the first quarter (Oct 1, 2025 - Dec 31, 2025) increased by 4.8% at constant currencies to EUR 240.2 million. On a reported basis, revenue grew by 3.8%. EBITDA amounted to EUR 65.2 million, representing a significant increase of 11.1%. The corresponding EBITDA margin reached 27.1% (Q1 2025: 25.4%).

“We are very pleased with our start to the 2026 financial year,” said Andreas Reisse, CEO of SCHOTT Pharma. “The first quarter performed slightly better than originally expected in terms of both revenue and earnings. Increased demand was visible across our portfolio, with the need for our high‑margin high-value solutions remaining strong. With HVS accounting for 57% of sales, we were able to build on the very good level achieved in the previous financial year. Despite ongoing uncertainties, we remain optimistic about the current financial year and confirm our revenue and earnings guidance for 2026.”

Reinhard Mayer, CFO of SCHOTT Pharma, added: “With our strategy focused on high‑value solutions, we once again achieved a very good profitability. This reinforces our decision to continue expanding our capacities in this area to meet the rising demand for sophisticated drug containment solutions and delivery systems.”

Profitable growth driven by high‑value solutions in DCS

The Drug Containment Solutions (DCS) segment, which includes glass vials, ampoules, and cartridges for storing injectable drugs, was the main driver of the positive development. With continued strong demand for sterile cartridges and specialty vials, the segment generated revenue of EUR 137.2 million, an increase of 9.4% at constant currencies (reported: 6.9%). HVS continued to perform very well, reaching a revenue share of 24%. EBITDA grew significantly by 18.9% to EUR 33.4 million, with volume and product‑mix effects more than offsetting ramp‑up costs linked to capacity relocations. The EBITDA margin rose to 24.3%, compared with 21.9% in the first quarter of 2025.